Q-omics provides the consensus-scored MTND4P32 profile across patient tissues and cancer cell-line models. MTND4P32 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, MTND4P32 is differentially expressed in 4, with the highest sampling consensus in STAD. Additionally, MTND4P32 RNA expression shows 13,481 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KICH, STAD, and LSCC as cancer lineages where MTND4P32 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MTND4P32 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MTND4P32 survival associations across molecular data types. MTND4P32 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MTND4P32 RNA expression–survival associations across cancer types. High MTND4P32 expression shows unfavorable associations in KICH, TGCT, MESO, READ, LUAD and UCEC. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for MTND4P32 RNA expression.
This table summarizes MTND4P32 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in STAD for RNA.
This table ranks reproducible tumor–normal expression differences for MTND4P32. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MTND4P32 shows higher tumor expression in STAD, BRCA, KICH and LUSC. The STAD box plot shows higher MTND4P32 RNA expression in tumor versus normal tissue (log2 FC = +0.075, t-test p = .004).
This table shows molecular features associated with MTND4P32 in patient tissues and cancer cell lines. In patient samples, MTND4P32 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
